chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Achy joint pain, sharp stabs of pain in joints; unsteady; nauseated; extreme tiredness; loss of appetite continuing for at least two days starting about 10 hours after injection.; The patient received a third/booster dose of BNT162b2.; This is a spontaneous report from a contactable consumer, the patient. A 77-year-old non-pregnant female patient received third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FE3592) via an unspecified route of administration in the left arm on 20Nov2021 at 11:30 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoarthritis, breast cancer which was treated, kidney cancer which was resolved and allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The concomitant medication included influenza vaccine (INFLUENZA) (Flu shot) for immunization on 16Nov2021. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 05Mar2021 at 11:45 (at the age of 77-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 23Mar2021 at 15:00 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. On 20Nov2021 at 21:30, about 10 hours after the vaccination, the patient experienced achy joint pain, sharp stabs of pain in joints, unsteady, nauseated, extreme tiredness and loss of appetite continuing for at least two days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events achy joint pain, sharp stabs of pain in joints, unsteady, nauseated, extreme tiredness and loss of appetite was not resolved at the time of this report.
fever 103 R;sl irritable, sleepy, pale, temp was high on 19APR & 20APR & on APAP;pt taken to MD 21APR;MD recommended DT for the 3rd dose
Case was vaccinated and boosted x2, and was then hospitalized for Covid treatment.  Hospitalized at:  Local facility. * Acute respiratory failure (HCC) Assessment & Plan We had suspected this was due to CAP and/ or COVID19 PNA. Now looks more like COVID PNA alone. Treatment as elsewhere.  Oxygen needs vacillate with activity and there may be a component of atelectasis as he had sats of 90% on RA in the afternoon on the 24 th and was 86-88% on RA at rest the am of discharge. Sats would improve to 92% after using IS ( does 3200 cc on IS)
Information has been received from a medical assistant referring to an unknown number of unspecified patients. On unknown dates starting on or after 12-MAY-2016 the patients were vaccinated with PROQUAD lot # L045675 (expiration date 09-MAY-2017) and Lot # M003434 (rHA, expiration date 19-JUL-2017), which was improperly stored at 14 F for 1400 minutes. There was no previous temperature excursion. No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Information has been received from a certified medical assistant concerning a 17 year old female with no pertinent medical history and no allergies who in December 2007, was vaccinated with the first dose of GARDASIL vaccine (yeast). In February 2008 the patient was vaccinated with the second dose of GARDASIL vaccine (yeast). There was no concomitant medication. The patient's mother asked if there have been reports of increase of frequency in the menstrual cycle. The patient's cycle was usually every 32 to 35 days but now it was every 27 days. On 25-JUN-2008, the patient was vaccinated with the third dose of GARDASIL vaccine (yeast). The patient's increase of frequency in the menstrual cycle persisted. The patient sought medical attention in office. Additional information has been requested.
constant headaches starting the day after shot was administered; This is a spontaneous report received from a contactable consumer, the patient. This 40-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the right arm on 24Mar2021 18:30 (at the age of 40-year-old) as single dose for COVID-19 immunization. The patient did not have any allergies to medications, food, or other products. Medical history included a head cold the week prior to the vaccination (Mar2021). Concomitant medications included pantoprazole and escitalopram. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 14:00, the patient experienced constant headaches starting the day after shot was administered. No treatment was received for the adverse event. The clinical outcome of the "constant headaches" was not resolved.    The lot number for the vaccine, BNT162b2, was not provided and will be requested during follow-up.
Initially, the next day after vaccine, the injection site became warm, red (approx 2 inch x 3 inch), swollen, & intensely  itchy which lasted approx. 2  days & considered that normal after having a vaccine.  However, 1 week after injection site had returned to normal it again became intensely itchy, swollen, red (approx 2 inch x 3 inch), & warm.
Swollen eyelids all the way from eyebrow to eyelashes, also swelling on side of nose.
Mother brought child in due to large lump on right side of neck. Child had a normal exam other than temp of 102.5 deg. F. and edema on right side of neck. Pt given Tylenol and parent told to use Tylenol at home for fevers. A follow up report received 5/10/2002 adds: State health department confirmed that this child did have mumps.
armpit deep red; she was in bed 5 days; joint pain; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (armpit deep red), BEDRIDDEN (she was in bed 5 days) and ARTHRALGIA (joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (armpit deep red), BEDRIDDEN (she was in bed 5 days) and ARTHRALGIA (joint pain). At the time of the report, ERYTHEMA (armpit deep red), BEDRIDDEN (she was in bed 5 days) and ARTHRALGIA (joint pain) outcome was unknown.            No concomitant medication was provided  Treatment medication was not provided by the reporter  It was reported that she would like to know if with the Moderna COVID-19 booster shot the immunity works as with the first two doses, that you had to wait 2 weeks to get full immunity   Most recent FOLLOW-UP information incorporated above includes: On 19-Nov-2021: Follow up received contains no new information.
The area was first noticed to be warm and red. Throughout the day it become more inflamed, painful and firm. Upon presentation to the urgent care the patient thigh was warm, red and firm from knee to hip with about 50% circumference. Parents also report patient is not acting himself, extremely fussy/irritable and decreased interactions.
8 cm by 8 cm area of warmth and redness on left arm, itchy Treatment - Motrin, cool compresses, Benadryl
This spontaneous report as received from a medical assistant refers to a patient of unknown demographics. Information regarding the patient's concurrent conditions and medical history was not provided. On 07-NOV-2016, the patient was inadvertently vaccinated with an expired dose of (wistar ra 27-3) M-M-R II which had a lot number of K018990 and expiration date on 15-OCT-2016 (route of administration and anatomical location were not reported). There were no concomitant medications provided. No adverse effects were reported. There was no product quality complaint involved. Additional information has been requested.
Pt reported she felt dizzy and nausea and had a pain and fullness in left ear. Slight edema under right eye. Pt  had no respiratory difficulties. Pt was went to the emergency department.  At the ED pt reported chest pain onset this morning prior to vaccine and feels similar to prior episodes of GERD. Chest pain is described as a pressure sensation. Denies tongue swelling, difficulty swallowing or speaking, rash, abdominal pain, nausea, vomiting.  On exam per ED note: no significant facial swelling noted, no tongue swelling.  EKG performed 6/9/21 pt in normal sinus rhythm. Chest xray 6/9, impression: Elevation right hemidiaphragm and low lung volumes. no radiographic evidence of acute cardiopulmonary process.  Pt did not want to wait in the ER and was angry about the wait time. Pt's breathing was easy and unlabored. Ambulatory out of ED with steady gait. Pt left ED.
Patient with single J+J vaccine 03/13/2021 who admitted after facial burns from smoking while using oxygen who had recently tested detected for COVID with subsequent COPD exacerbation.  Provider discharge note below: "61 YO male with end-stage COPD presented to ED with facial burns related to smoking with supplemental O2.  Found to have hypoxia worse than baseline with covid infection causing COPD exacerbation.  Treated with dexamethasone and remdesivir.  Prolonged stay due to COPD exacerbation, anxiety about discharge with end-stage COPD causing severely limited functional capacity.  Palliative and Pulmonary consults.  Patient is hospice appropriate but refusing at this time.  Significant discussion regarding goals of care and anxiety about discharge.  Will continue to follow at home.  "
Large area 6 1/2 inches in diameter red and slightly warm, non tender. Child can walk, even walk without difficulty.
Arm swelling, pain, redness. Diagnosis cellulitis, leukocytosis. Treatment Morphine, Zosyn IV, Zyrtec, Solumedrol IV, Benadryl. Ice to arm. DOS 8/18/06-8/22/06. DC DX multi-level cervical and lumbar spinal arthritis as well as thoracic spine. T-12 compression fracture, probably old, of 50%. Mild disc disease in cervical area with background of Parkinson's disease, hypertension, gastritis, insomnia. Complaints: admitted with generalized joint pain. Fallen approximately 4 times, blacked out. Multiple bruises and abrasions over right hip and both forearm. Back pain.  PE: WNL other than noted above.  Neurology Consult: Impression: chronic dizziness, history of Parkinson's disease, hypertension, arthritis, GERD, anxiety, depression. Cardiology Consult: Impression: chronic dizziness of uncertain etiology, recent loss of consciousness sounds orthostatic in origin, hypertension, GERD, parkinsonism, history of low back pain with herniated discs. Telemetry strips shows sinus rhythm with dysrhythmias. DC DX for DOS8/24-8/27/06 Drug reaction to pneumococcal vaccine, possible cellulitis, Parkinson's disease, degenerative disease of back. Received pneumonia shot during most recent hospitalization. Developed redness in posterial aspect of right arm, worsened seen in ER for possible cellulitis. Started on IV antibiotics. Symptoms did not change much however, with 2 doses of IV steroids they improved significantly.  Current medications: Metoprolol, Lyrica, omeprazole, Sinemet, Ambien. Allergic to Codeine and Hydrocodone.    DC DX multi-level cervical and lumbar spinal arthritis as well as thoracic spine. T-12 compression fracture, probably old, of 50%. Mild disc disease in cervical area with background of Parkinson's disease, hypertension, gastritis, insomnia. Complaints: admitted with generalized joint pain. Fallen approximately 4 times, blacked out. Multiple bruises and abrasions over right hip and both forearm. Back pain.  PE: WNL other than noted above.  Neurology Consult: Impression: chronic dizziness, history of Parkinson's disease, hypertension, arthritis, GERD, anxiety, depression. Cardiology Consult: Impression: chronic dizziness of uncertain etiology, recent loss of consciousness sounds orthostatic in origin, hypertension, GERD, parkinsonism, history of low back pain with herniated discs. Telemetry strips shows sinus rhythm with dysrhythmias. DC DX for DOS8/24-8/27/06 Drug reaction to pneumococcal vaccine, possible cellulitis, Parkinson's disease, degenerative disease of back. Received pneumonia shot during most recent hospitalization. Developed redness in posterial aspect of right arm, worsened seen in ER for possible cellulitis. Started on IV antibiotics. Symptoms did not change much however, with 2 doses of IV steroids they improved significantly.  Current medications: Metoprolol, Lyrica, omeprazole, Sinemet, Ambien.
The vaccine caused a strong site reaction. Right deltoid was swollen and left a rash. Patient felt dizzy for the first 10 minutes but stabilized.
1 3/4" x 2" pink skin marking non tender/not indurated] rt LUT deltoud immunization site.
Fever 101.7F; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever 101.7F) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced PYREXIA (Fever 101.7F). At the time of the report, PYREXIA (Fever 101.7F) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Mar-2021, Body temperature: 107.7 f (Inconclusive) Fever 101.7 F.         Action taken with mRNA-1273 in response to the events was not applicable. Concomitant information were not provided by the reporter. Treatment information were not provided by the reporter.
INJECTION SITE RED & SWOLLEN. CALCIFIED HEMATOMA. WARM COMPRESS & MASSAGE 3 X A DAY.
Initial report received on 30 May 2013 from the Investigator participating in the post-marketing study under the reference number M5A16. A case of pertussis disease in a 3-year-old male subject (initials not collected) was identified by the investigator based on review of data from the Electronic Disease Surveillance (EDS) electronic database. The subject had received 4 doses of PENTACEL on 18 February 2010, 21 April 2010, 07 July 2010, and 13 April 2011 (lot numbers, routes and sites of administration not reported). The subject developed a cough on 06 May 2013, approximately 2 years after the last dose, and a paroxysmal cough without a whoop on 06 May 2013. The subject also developed cold like symptoms on 05 May 2013 and post tussive vomiting and apnea (start dates not reported). Laboratory testing included positive PCR on 08 May 2013. Chest x-ray findings were negative for pneumonia. Corrective treatments consisted of azithromycin starting on 11 May 2013 for 5 days. The subject was not hospitalized. At the time of final contact on 22 May 2013, the subject's cough was still persisting. The duration of the cough was reported at that time as 16 days. Investigator causality assessment is not required as per protocol. Documents held by sender: None.
it felt like her nerve endings in her arms and legs were pulsating; Hard lumps; Hard lumps and very bumpy feel and also extremely itchy; Painful Rash; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL NERVE NEUROSTIMULATION (it felt like her nerve endings in her arms and legs were pulsating), SKIN MASS (Hard lumps), PRURITUS (Hard lumps and very bumpy feel and also extremely itchy) and RASH (Painful Rash) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025A21A and 016M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH (Painful Rash). On an unknown date, the patient experienced PERIPHERAL NERVE NEUROSTIMULATION (it felt like her nerve endings in her arms and legs were pulsating), SKIN MASS (Hard lumps) and PRURITUS (Hard lumps and very bumpy feel and also extremely itchy). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, PERIPHERAL NERVE NEUROSTIMULATION (it felt like her nerve endings in her arms and legs were pulsating), SKIN MASS (Hard lumps) and PRURITUS (Hard lumps and very bumpy feel and also extremely itchy) outcome was unknown and RASH (Painful Rash) was resolving.            Concomitant product use was not provided by the reporter.  The patient experienced arms and legs felt like gravel roads, there were Hard lumps and very bumpy feel. The rash was extremely painful as well and it felt like her nerve endings in arms and legs were pulsating.  The patient received both scheduled doses of mRNA-1273 prior to the events therefore, action taken with the drug in response to the event is not applicable.
about an hour after receiving the vaccine, her son vomited.; This spontaneous report was received from a pharmacist referring to her son, a 6 month old male patient.  The patient did not have pertinent medical history or concomitant medication or drug reactions or allergies.     On 29-OCT-2021, the patient was vaccinated with the 3rd dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 2ml, orally, for prevention of rotavirus (lot/batch # and expiration date were not reported).    She reported that about an hour after receiving the vaccine, on the same date, her son vomited (vomiting).  The patient did not seek medical attention and did not received treatment.   The outcome of vomiting was reported as resolved on the same date.  The causal relationship between the event and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was not provided.
This case was reported by a physician via call center representative and described the occurrence of knee pain in a 12-year-old male patient who received RABAVERT. Concomitant products included RABAVERT and RABAVERT. In July 2015, the patient received the 3rd dose of RABAVERT. In July 2015, less than a month after receiving RABAVERT and less than a year after receiving RABAVERT, the patient experienced knee pain, neurological disorder nos, stiffness, fatigue and walking difficulty. On an unknown date, the outcome of the knee pain, neurological disorder nos, stiffness, fatigue and walking difficulty were not recovered/not resolved. It was unknown if the reporter considered the knee pain, neurological disorder nos, stiffness, fatigue and walking difficulty to be related to RABAVERT. Additional details were provided as follows: On 26th June 2015, the patient received the 1st dose of RABAVERT. On 29th June 2015, the patient received the 2nd dose of RABAVERT. In July 2015, the patient received the 3rd dose of RABAVERT (the reporter was unsure but thought he did received it). Approximately 5 to 6 months before 27th January 2016, i.e., in July 2015, the patient experienced bilateral knee pain, struggling with walking, unable to run, difficulty going up and down stairs with using hand rails, stiffness, fatigue and neurological decline. The emergency medical attention was not required. The product information for previous dose of RABAVERT was unknown. The additional information would be available on follow up.
migraines; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (migraines) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (migraines). At the time of the report, MIGRAINE (migraines) had not resolved.            Patient had last dose of the Moderna vaccine 2 months ago. No concomitant medication was reported by the reporter. No treatment was reported by the reporter.   Reporter did not allow further contact
Dizzy & diaphoretic after vaccine, bp checked 190/110, taken to ED.   Ed workup with ECG - normal, patient was monitored, symptoms resolved.
Suspected vaccination failure; Shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had years ago from the date of reporting).   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria hospitalization and GSK medically significant) and shingles (serious criteria hospitalization). On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The patient had reported for him/herself. The age at vaccination was not reported. The patient had shingles and had shingles shots years ago from the date of reporting. After receiving Shingles vaccine, the patient got shingles while in the hospital and lasted for weeks. The patient thought he/she would never get shingles again and stated that, they drive you crazy. This case was considered as suspected vaccination failure, since the details regarding time to onset for event and laboratory confirmation of shingles were not provided.
Upon leaving the appointment, my daughter expressed that she could ?feel it going through her body?. Within a an hour or so she was feeling tired, sluggish and pain in the shot site and aches throughout her body by mid afternoon.   Couldn?t control the body aches and pain through day/night. Fever present. (Flu-like symptoms)
Severe fatigue, severe nausea, vomiting, joint pain, muscle ache, pain in armpit, injection site pain and dizziness and migraine.  Symptoms were minor on the day of the vaccine but severe the following two days.
I have severe side effects from the Janssen COVID-19 Vaccine EUA. My face is itchy, swelling, has redness, has a burning sensation, some numbness on a swollen spot on my jaw, and the injection spot is swollen.
Patient experienced bruising size of orange for 1 week along with sore arm, neck muscles and back muscles for an entire week. Had difficulty completing activities of daily living for one week because of arm discomfort.
Pt. recieved th e Pfizer Bivalent booster instead of the Monovalent vaccine for her second dose in the primary series.
Please select any symptoms you are experiencing:  Fever or Chills  Fatigue  Muscle or body aches  Headache  Sore throat